

Dated: March 8, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.
[FR Doc. 95-6126 Filed 3-8-95; 4:20 pm]

BILLING CODE 4160-01-F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Vaccines and Related Biological Products Advisory Committee

Date, time, and place. March 17, 1995, 3 p.m., Food and Drug Administration, Bldg. 29, conference room 121, 8800 Rockville Pike, Bethesda, MD.

Type of meeting and contact person. This meeting will be held by a telephone conference call. A speaker telephone will be provided in the conference room to allow public participation in the meeting. Open committee discussion, 3 p.m. to 4:30 p.m.; open public hearing, 4:30 p.m. to 5:30 p.m., unless public participation does not last that long; Nancy T. Cherry or Stephanie A. Milwit, Center for Biologics Evaluation and Research (HFM-21), Food and Drug Administration, 1401 Rockville Pike,

Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), Vaccines and Related Biological Products Advisory Committee, code 12388.

General function of the committee.

The committee reviews and evaluates data on the safety and effectiveness of vaccines intended for use in the diagnosis, prevention, or treatment of human diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person.

Open committee discussion. The committee will discuss the influenza virus vaccine formulation for 1995-1996.

FDA regrets that it was unable to publish this notice 15 days prior to the March 17, 1995, Vaccines and Related Biological Products Advisory Committee meeting because of the need to update the committee on late developing influenza activity and to formulate a vaccine for the 1995-1996 year based on that data while providing manufacturers sufficient lead time to develop and produce the vaccine. This meeting is a followup to the January 1995 advisory committee meeting. The agency decided that it was in the public interest to hold this meeting in mid-March even if there was not sufficient time for the customary 15-day public notice.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee

chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: March 7, 1995

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95-6061 Filed 3-10-95; 8:45 am]

BILLING CODE 4160-01-F

Health Care Financing Administration

[BPD-833-N]

Medicare Program; Hospice Wage Index

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Notice of meetings.

SUMMARY: In accordance with section 10(a) of the Federal Advisory Committee Act (FACA), this notice announces two meetings of the Negotiated Rulemaking Advisory Committee on the Medicare Hospice Wage Index. The meetings are open to the public.

DATES: The March meeting is scheduled for March 22, 1995, from 10 a.m. until 5 p.m. e.s.t., and March 23, 1995, from 9 a.m. until 3 p.m. The April meeting is scheduled for April 11, 1995, from 10 a.m. until 5 p.m. e.s.t., April 12, 1995, from 9 a.m. until 5 p.m., and April 13, 1995, from 9 a.m. until 3 p.m.

ADDRESSES: The meetings will be held at the Sheraton City Center, 1143 New Hampshire Avenue NW., Washington, DC 20037.

FOR FURTHER INFORMATION CONTACT: Jennifer Carter, (410) 966-4615.

SUPPLEMENTARY INFORMATION: Under the authority of the Negotiated Rulemaking Act of 1990 (Pub. L. 101-648, 5 U.S.C. 581-590), the Secretary of the Department of Health and Human Services has established the Negotiated Rulemaking Advisory Committee on the Medicare Hospice Wage Index. The Committee will make recommendations with respect to the content of a proposed rule on the wage index used to adjust payment rates for hospice care under the Medicare program to reflect local differences in area wage levels. The Committee consists of representatives of interests that are likely to be significantly affected by the proposed rule.

The Committee will meet on March 22-23 and April 11-13, 1995. The Committee will undertake the following activities:

- Discussion of analyses using Bureau of Labor Statistics data.
- Review issues in light of the BLS and hospital data.
- Attempt to develop a consensus document.

Individuals or organizations who wish to attend the meeting or make oral

presentations may do so. However, the number of presentations may be limited by the time available. Individuals may also submit written statements for the Committee's consideration. For information on how to do this, please contact the Committee facilitator, Judy Ballard at (202) 690-7419.

(Section 10(a) of Public Law 92-463 (5 U.S.C. App. 2, section 10(a)); 45 CFR Part 11

(Catalog of Federal Domestic Assistance Program No. 93.773 Medicare—Hospital Insurance Program)

Dated: March 7, 1995.

Bruce C. Vladek,

Administrator, Health Care Financing Administration.

[FR Doc. 95-6083 Filed 3-8-95; 12:34 pm]

BILLING CODE 4120-01-P

National Institutes of Health

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda

To review individual grant applications.

Name of SEP: Clinical Sciences.

Date: March 29, 1995.

Time: 1 p.m.

Place: NIH, Westwood Building, Room 352, Telephone Conference.

Contact Person: Dr. Gertrude McFarland, Scientific Review Admin., 5333 Westbard Ave., Room 352, Bethesda, MD 20892; (301) 594-7080.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 11, 1995.

Time: 2 p.m.

Place: NIH, Westwood Building, Room 226, Telephone Conference.

Contact Person: Dr. Gerald Liddel, Scientific Review Administrator, 5333 Westbard Ave., Room 226, Bethesda, MD 20892; (301) 594-7167.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 12, 1995.

Time: 1 p.m.

Place: NIH, Westwood Building, Room 226, Telephone Conference.

Contact Person: Dr. Gerald Liddel, Scientific Review Administrator, 5333 Westbard Ave., Room 226, Bethesda, MD 20892; (301) 594-7167.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material

and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-6056 Filed 3-10-95; 8:45 am]

BILLING CODE 4140-01-M

Social Security Administration

Privacy Act of 1974, as Amended; Computer Matching Program (SSA/Railroad Retirement Board)

AGENCY: Social Security Administration, HHS.

ACTION: Notice of computer matching program.

SUMMARY: In accordance with the provisions of the Privacy Act, as amended, this notice announces a computer matching program that SSA plans to conduct.

DATES: SSA will file a report of the subject matching program with the Committee on Governmental Affairs of the Senate, the Committee on Government Reform and Oversight of the House of Representatives and the Office of Information and Regulatory Affairs, Office of Management and Budget. The matching program will be effective as indicated below.

ADDRESSES: Interested parties may comment on this notice by either facsimile to (410) 966-5138, or writing to the Associate Commissioner for Program and Integrity Reviews, 860 Altmeyer Building, 6401 Security Boulevard, Baltimore, MD 21235. All comments received will be available for public inspection at this address.

FOR FURTHER INFORMATION CONTACT: The Associate Commissioner for Program and Integrity Reviews as shown above.

SUPPLEMENTARY INFORMATION:

A. General

The Computer Matching and Privacy Protection Act of 1988 (Pub. L. 100-503), amended the Privacy Act (5 U.S.C. 552a) by adding certain protections for